Chimerix (CMRX) Competitors $3.55 -0.11 (-3.01%) As of 01/17/2025 04:00 PM Eastern Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends CMRX vs. CALT, DAWN, PRAX, ANIP, SPRY, AUPH, COLL, SNDX, SYRE, and ELVNShould you be buying Chimerix stock or one of its competitors? The main competitors of Chimerix include Calliditas Therapeutics AB (publ) (CALT), Day One Biopharmaceuticals (DAWN), Praxis Precision Medicines (PRAX), ANI Pharmaceuticals (ANIP), ARS Pharmaceuticals (SPRY), Aurinia Pharmaceuticals (AUPH), Collegium Pharmaceutical (COLL), Syndax Pharmaceuticals (SNDX), Spyre Therapeutics (SYRE), and Enliven Therapeutics (ELVN). These companies are all part of the "pharmaceutical products" industry. Chimerix vs. Calliditas Therapeutics AB (publ) Day One Biopharmaceuticals Praxis Precision Medicines ANI Pharmaceuticals ARS Pharmaceuticals Aurinia Pharmaceuticals Collegium Pharmaceutical Syndax Pharmaceuticals Spyre Therapeutics Enliven Therapeutics Calliditas Therapeutics AB (publ) (NASDAQ:CALT) and Chimerix (NASDAQ:CMRX) are both small-cap medical companies, but which is the superior stock? We will compare the two companies based on the strength of their community ranking, earnings, risk, institutional ownership, valuation, media sentiment, analyst recommendations, dividends and profitability. Do analysts prefer CALT or CMRX? Calliditas Therapeutics AB (publ) presently has a consensus target price of $39.25, indicating a potential downside of 1.88%. Chimerix has a consensus target price of $8.50, indicating a potential upside of 139.44%. Given Chimerix's stronger consensus rating and higher possible upside, analysts plainly believe Chimerix is more favorable than Calliditas Therapeutics AB (publ).Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Calliditas Therapeutics AB (publ) 0 Sell rating(s) 5 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00Chimerix 0 Sell rating(s) 0 Hold rating(s) 2 Buy rating(s) 0 Strong Buy rating(s) 3.00 Which has higher valuation and earnings, CALT or CMRX? Calliditas Therapeutics AB (publ) has higher revenue and earnings than Chimerix. Calliditas Therapeutics AB (publ) is trading at a lower price-to-earnings ratio than Chimerix, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioCalliditas Therapeutics AB (publ)$1.60B0.74-$43.96M-$1.85-21.62Chimerix$320K997.77-$82.10M-$0.94-3.78 Does the MarketBeat Community favor CALT or CMRX? Chimerix received 367 more outperform votes than Calliditas Therapeutics AB (publ) when rated by MarketBeat users. Likewise, 63.86% of users gave Chimerix an outperform vote while only 55.10% of users gave Calliditas Therapeutics AB (publ) an outperform vote. CompanyUnderperformOutperformCalliditas Therapeutics AB (publ)Outperform Votes2755.10% Underperform Votes2244.90% ChimerixOutperform Votes39463.86% Underperform Votes22336.14% Which has more risk & volatility, CALT or CMRX? Calliditas Therapeutics AB (publ) has a beta of 1.77, suggesting that its stock price is 77% more volatile than the S&P 500. Comparatively, Chimerix has a beta of 0.36, suggesting that its stock price is 64% less volatile than the S&P 500. Do institutionals and insiders believe in CALT or CMRX? 2.8% of Calliditas Therapeutics AB (publ) shares are held by institutional investors. Comparatively, 45.4% of Chimerix shares are held by institutional investors. 2.2% of Calliditas Therapeutics AB (publ) shares are held by insiders. Comparatively, 13.1% of Chimerix shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term. Does the media prefer CALT or CMRX? In the previous week, Chimerix had 3 more articles in the media than Calliditas Therapeutics AB (publ). MarketBeat recorded 3 mentions for Chimerix and 0 mentions for Calliditas Therapeutics AB (publ). Chimerix's average media sentiment score of 0.97 beat Calliditas Therapeutics AB (publ)'s score of 0.00 indicating that Chimerix is being referred to more favorably in the news media. Company Overall Sentiment Calliditas Therapeutics AB (publ) Neutral Chimerix Positive Is CALT or CMRX more profitable? Chimerix has a net margin of 0.00% compared to Calliditas Therapeutics AB (publ)'s net margin of -30.18%. Chimerix's return on equity of -50.78% beat Calliditas Therapeutics AB (publ)'s return on equity.Company Net Margins Return on Equity Return on Assets Calliditas Therapeutics AB (publ)-30.18% -212.04% -27.96% Chimerix N/A -50.78%-44.94% SummaryChimerix beats Calliditas Therapeutics AB (publ) on 14 of the 18 factors compared between the two stocks. Get Chimerix News Delivered to You Automatically Sign up to receive the latest news and ratings for CMRX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart CMRX vs. The Competition Export to ExcelMetricChimerixPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$319.29M$6.35B$5.24B$9.00BDividend YieldN/A2.94%5.13%4.03%P/E Ratio-3.785.2665.3814.27Price / Sales997.77334.891,272.1186.92Price / CashN/A61.4443.8235.97Price / Book1.646.055.324.80Net Income-$82.10M$154.62M$122.68M$224.91M7 Day Performance9.23%-1.70%-0.21%1.47%1 Month Performance31.00%2.75%3.72%4.66%1 Year Performance285.74%2.60%27.18%20.83% Chimerix Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)CMRXChimerix4.4946 of 5 stars$3.55-3.0%$8.50+139.4%+277.6%$319.29M$320,000.00-3.7890Short Interest ↓Gap DownCALTCalliditas Therapeutics AB (publ)N/A$40.00flat$39.25-1.9%N/A$1.19B$1.60B-21.62180DAWNDay One Biopharmaceuticals1.7779 of 5 stars$11.78-0.2%$35.86+204.4%-9.2%$1.19BN/A-11.4460News CoveragePRAXPraxis Precision Medicines2.0414 of 5 stars$62.17-1.6%$146.33+135.4%+80.8%$1.16B$1.61M-6.04110Short Interest ↑Gap DownANIPANI Pharmaceuticals4.4767 of 5 stars$54.67-0.7%$77.71+42.2%+5.1%$1.15B$555.46M-99.40600Short Interest ↓Gap DownSPRYARS Pharmaceuticals2.835 of 5 stars$11.57+2.9%$24.50+111.8%+106.4%$1.12B$2.57M-22.6990Analyst ForecastAUPHAurinia Pharmaceuticals2.286 of 5 stars$7.80-3.3%$10.00+28.2%+1.8%$1.12B$220.36M-52.00300Positive NewsCOLLCollegium Pharmaceutical4.2086 of 5 stars$33.84+2.8%$43.80+29.4%+1.9%$1.09B$599.25M14.59210Insider TradeSNDXSyndax Pharmaceuticals3.7286 of 5 stars$12.77-2.6%$36.20+183.5%-39.6%$1.09B$16M-3.52110Short Interest ↑News CoverageSYRESpyre Therapeutics2.1548 of 5 stars$21.05-6.3%$51.50+144.7%-4.4%$1.08B$890,000.00-2.82100Analyst RevisionELVNEnliven Therapeutics2.2592 of 5 stars$22.09+1.6%$38.25+73.2%+91.0%$1.08BN/A-11.6350 Related Companies and Tools Related Companies Calliditas Therapeutics AB (publ) Competitors Day One Biopharmaceuticals Competitors Praxis Precision Medicines Competitors ANI Pharmaceuticals Competitors ARS Pharmaceuticals Competitors Aurinia Pharmaceuticals Competitors Collegium Pharmaceutical Competitors Syndax Pharmaceuticals Competitors Spyre Therapeutics Competitors Enliven Therapeutics Competitors Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:CMRX) was last updated on 1/18/2025 by MarketBeat.com Staff From Our PartnersLast time you’ll see this priced at $1.00When was the last time you bought something for a buck? I don’t even think you can buy anything at McDonalds f...StocksToTrade | SponsoredDo this Before Elon’s Reveal on January 22ndElon’s newest tech could pay you an extra $30,000 a year — while you sleep. It’s smaller than a quarter but...Brownstone Research | SponsoredGrab This Altcoin Before Trump's Crypto AnnouncementGrab This Altcoin Before Trump's Crypto Announcement Whatever it is, I expect it to pump the market, which ...Crypto 101 Media | SponsoredTrump Insider: Day One will Shock EveryoneA rare opportunity for everyday Americans like you to turn a small stake into real wealth in the stock market....InvestorPlace | Sponsored“Fed Proof” Your Bank Account with THESE 4 Simple StepsStarting as soon as a few months from now, the United States government will make a sweeping change to bank ac...Weiss Ratings | SponsoredInvesting Tools You’ll Need for 2025Investing Tools You’ll Need for 2025 Charles Payne Shares His #1 Strategy for 2025 Unstoppable Prosperity | SponsoredBitcoin to $200K?Newsweek recently asked several analysts whether they think Bitcoin will hit $200,000 by the end of 2025. T...Stansberry Research | SponsoredElon's "Final Move" Could Send This Stock SoaringWhenever Elon Musk starts a new venture... Early investors get the opportunity to become millionaires... ...Behind the Markets | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Chimerix, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Chimerix With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CMRX Stock Alerts